Jash Datta, GI Surgical Oncologist and Associate Professor at Sylvester Comprehensive Cancer Center, shared by Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, on X:
“BOT – which is Fc engineered CTLA-4 Ab – and BAL in MSS localized CRC NEST2 trial.
Opens up vistas for application of immunotherapy in non-MSI solid cancers”
Quoting Pashtoon Kasi:
“Unveiling FULL results of our NEST Trial in MSS ‘cold’ colorectal cancer Immunotherapy (BOT /BAL) BEFORE surgery % disease-free to date
NEST1:~32 months
NEST2:~24 months
5 years of work – now in CCR_AACR
NEST3 NOW OPEN!
Title: Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
Authors: Manish A. Shah, Erika Hissong, Mehraneh D. Jafari, Pashtoon Murtaza Kasi, Maider Astorkia, Sahrish Khan, Casey Owens, Zhengming Chen, Heather Yeo, Fabio Socciarelli, Sandipto Sarkar, Alana Nguyen, Despina Siolas, Allyson Ocean, Kelly Garrett, Lea Lowenfeld, Alessio Pigazzi, Preethi Guniganti, Sanjay Patel, Doron Betel, Manuel Hidalgo
You can also read:Tumor Mutational Burden Predicts Response to Neoadjuvant Immunotherapy
